Korea FDA To Consider Substantial Reduction To IND Timeframe
This article was originally published in PharmAsia News
Executive Summary
As Korea competes with neighboring countries to be a regional clinical trial hub, KFDA weighs the advantages of slashing IND timelines from 30 days down to 14 days.
You may also be interested in...
Korea FDA Prepares Guidelines On Phase 0 Clinical Trials To Draw More Early-stage Trials
SEOUL - Korea FDA is gearing up to release guidelines on Phase 0 clinical trials in the first half of next year under its broader ambition to draw more early-stage clinical trials to the country
Korean Government Shifts Attention To CRO Sector In Steady Drive To Build Up Biotech Infrastructure, Biosimilars
SEOUL - After realizing that it was a late comer, the Korean government is now moving to strengthen its local CRO industry to support a clinical trial infrastructure that is bursting at the seams as MNCs flock to Korea to conduct early-stage trials
Asia Pacific Key To Speeding Up Global Drug Development, Says Quintiles VP Anand Tharmaratnam (Part 1 Of 2)
Globalization of clinical trials is perhaps Asia's main role in advancing the pharmaceutical industry, says Quintiles Asia Pacific Head of Clinical Development Anand Tharmaratnam, who discussed innovation in Asia Pacific with PharmAsia News' Australia Bureau. Key to that innovation is a lack of legacy informationin that the past is not holding the industry back, and virtual opportunitiesand private/public cooperative partnerships offer ripe benefits.